248 related articles for article (PubMed ID: 35817971)
1. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
[TBL] [Abstract][Full Text] [Related]
2. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
[TBL] [Abstract][Full Text] [Related]
5. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
[TBL] [Abstract][Full Text] [Related]
6. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
[TBL] [Abstract][Full Text] [Related]
7. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
[No Abstract] [Full Text] [Related]
8. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
[TBL] [Abstract][Full Text] [Related]
9. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
10. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
[TBL] [Abstract][Full Text] [Related]
11. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1.
Buchanan DD; Stewart JR; Clendenning M; Rosty C; Mahmood K; Pope BJ; Jenkins MA; Hopper JL; Southey MC; Macrae FA; Winship IM; Win AK
Genet Med; 2018 Aug; 20(8):890-895. PubMed ID: 29120461
[TBL] [Abstract][Full Text] [Related]
12. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
Bellido F; Pineda M; Aiza G; Valdés-Mas R; Navarro M; Puente DA; Pons T; González S; Iglesias S; Darder E; Piñol V; Soto JL; Valencia A; Blanco I; Urioste M; Brunet J; Lázaro C; Capellá G; Puente XS; Valle L
Genet Med; 2016 Apr; 18(4):325-32. PubMed ID: 26133394
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Rousseau B; Bieche I; Pasmant E; Hamzaoui N; Leulliot N; Michon L; de Reynies A; Attignon V; Foote MB; Masliah-Planchon J; Svrcek M; Cohen R; Simmet V; Augereau P; Malka D; Hollebecque A; Pouessel D; Gomez-Roca C; Guimbaud R; Bruyas A; Guillet M; Grob JJ; Duluc M; Cousin S; de la Fouchardiere C; Flechon A; Rolland F; Hiret S; Saada-Bouzid E; Bouche O; Andre T; Pannier D; El Hajbi F; Oudard S; Tournigand C; Soria JC; Champiat S; Gerber DG; Stephens D; Lamendola-Essel MF; Maron SB; Diplas BH; Argiles G; Krishnan AR; Tabone-Eglinger S; Ferrari A; Segal NH; Cercek A; Hoog-Labouret N; Legrand F; Simon C; Lamrani-Ghaouti A; Diaz LA; Saintigny P; Chevret S; Marabelle A
Cancer Discov; 2022 Jun; 12(6):1435-1448. PubMed ID: 35398880
[TBL] [Abstract][Full Text] [Related]
14. Distinctive genomic characteristics in
He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
[TBL] [Abstract][Full Text] [Related]
16. Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.
Weber CAM; Krönke N; Volk V; Auber B; Förster A; Trost D; Geffers R; Esmaeilzadeh M; Lalk M; Nabavi A; Samii A; Krauss JK; Feuerhake F; Hartmann C; Wiese B; Brand F; Weber RG
Acta Neuropathol Commun; 2023 Nov; 11(1):184. PubMed ID: 37990341
[TBL] [Abstract][Full Text] [Related]
17. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
[TBL] [Abstract][Full Text] [Related]
18. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
[TBL] [Abstract][Full Text] [Related]
19. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
[TBL] [Abstract][Full Text] [Related]
20. Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort.
Khan N; Lipsa A; Arunachal G; Ramadwar M; Sarin R
Sci Rep; 2017 May; 7(1):2214. PubMed ID: 28533537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
